Alcohol Withdrawal — ED to Inpatient Management

Key Points

• Benzodiazepines are first-line treatment for alcohol withdrawal and prevent recurrent withdrawal seizures and delirium.
• A history of withdrawal seizure or delirium predicts a higher-risk future course and should lower the threshold for monitored treatment.
• CIWA-Ar should not be used when the patient cannot communicate reliably or is delirious.
• Symptom-triggered dosing is effective in appropriate monitored patients, but fixed or front-loaded treatment is safer in selected high-risk cases.
• Use lorazepam or oxazepam preferentially when severe liver dysfunction makes long-acting active metabolites undesirable.
• Thiamine is important, but hypoglycemia should be corrected immediately even if thiamine is not yet available.
• Phenytoin is ineffective for preventing recurrent seizures caused solely by alcohol withdrawal.
• Withdrawal treatment should transition directly into evidence-based alcohol use disorder care.

Algorithm

1. Assess current symptoms, time since last alcohol use, prior complicated withdrawal, comorbidity, and other possible diagnoses.
2. Check glucose and targeted labs; treat trauma, infection, metabolic disease, or intoxication in parallel.
3. Classify withdrawal as mild, moderate, severe, seizure-complicated, or delirium and select the appropriate monitoring setting.
4. Administer benzodiazepines using a symptom-triggered, fixed-dose, or front-loading strategy suited to the patient.
5. Give thiamine and correct measured electrolyte, fluid, and nutritional deficiencies.
6. Escalate to ICU-level care for delirium, recurrent seizures, severe autonomic instability, respiratory compromise, or very high sedative requirements.
7. Once stable, reassess cognition and psychiatric safety and diagnose alcohol use disorder when criteria are met.
8. Offer medications for alcohol use disorder and arrange follow-up, peer support, or addiction treatment before discharge.

Clinical Synopsis & Reasoning

Symptoms often begin within hours of the last drink and include tremor, anxiety, insomnia, diaphoresis, nausea, tachycardia, and hypertension. Generalized withdrawal seizures most often occur within the first 6 to 48 hours, while alcohol withdrawal delirium usually appears later and features fluctuating attention, disorientation, marked autonomic activation, and often hallucinations. Timeline varies with amount consumed, concurrent sedatives, liver disease, prior withdrawal, and intercurrent illness. Ask specifically about prior seizures, delirium tremens, ICU admission, benzodiazepine use, other substance withdrawal, and recent alcohol intake. Do not attribute every agitation or tachycardia in a person who drinks heavily to withdrawal. Evaluate for infection, head injury, GI bleeding, pancreatitis, hypoglycemia, ketoacidosis, hepatic encephalopathy, stimulant intoxication, sedative-hypnotic withdrawal, and other emergencies. CIWA-Ar is useful only in communicative patients who can provide reliable symptom reports; it is inappropriate in delirium, severe cognitive impairment, intubation, or many critically ill patients. In those settings use objective sedation and autonomic measures and clinician-directed dosing.

Treatment Strategy & Disposition

Use benzodiazepines as first-line pharmacotherapy. Symptom-triggered dosing can reduce medication exposure in appropriately selected monitored patients, while fixed-dose or front-loading strategies are often safer for patients at high risk, those with unreliable scoring, or severe withdrawal. Diazepam and chlordiazepoxide provide long action and self-tapering in patients without major hepatic impairment; lorazepam or oxazepam are often preferred when severe liver disease increases concern for active metabolites. Phenobarbital can be used in experienced settings as monotherapy or adjunct according to a protocol, but respiratory depression and cumulative sedation require close monitoring. Give thiamine to patients with heavy alcohol use or malnutrition risk, preferably before or with glucose, but never delay treatment of hypoglycemia to administer thiamine first. Replete magnesium, phosphate, potassium, and fluids according to measured deficits rather than routinely. Withdrawal seizures are treated with benzodiazepines; phenytoin does not prevent recurrent pure alcohol-withdrawal seizures unless there is a separate seizure disorder. Delirium tremens requires aggressive sedative treatment and often ICU care. Once stabilized, offer medications and behavioral treatment for alcohol use disorder and arrange continuity of care.

Epidemiology / Risk Factors

• Alcohol withdrawal is common in emergency and inpatient settings because abrupt abstinence often occurs during acute illness or hospitalization.
• Repeated withdrawal episodes may become more severe over time, a phenomenon commonly described as kindling.
• Malnutrition, liver disease, electrolyte abnormalities, trauma, and infection frequently coexist with alcohol use disorder.
• Withdrawal seizures are typically generalized and brief; focal or prolonged seizures require evaluation for another cause.
• Delirium tremens is less common than uncomplicated withdrawal but carries significant morbidity without prompt treatment.

Investigations

Common Benzodiazepine Strategies

Pharmacology

Prognosis / Complications

• Uncomplicated withdrawal usually resolves over several days with appropriate treatment.
• Seizures and delirium indicate a higher-risk course and often require inpatient or ICU management.
• Mortality from treated withdrawal delirium is low in modern monitored care but rises with delayed recognition, comorbidity, and complications.
• The largest long-term risk after detoxification is recurrence of heavy alcohol use if alcohol use disorder is not treated.
• Starting evidence-based AUD treatment during hospitalization improves the chance that acute withdrawal care leads to sustained benefit.

Patient Education / Counseling

• Explain that withdrawal can become more severe even after initial symptoms improve, especially in patients with previous seizures or delirium.
• Advise against self-detoxification when there is a history of complicated withdrawal, serious medical illness, pregnancy, or unreliable support.
• Discuss thiamine and nutrition and provide clear guidance on prescribed benzodiazepine use if outpatient treatment is selected.
• Offer medications for alcohol use disorder such as naltrexone, acamprosate, or another appropriate option after contraindications and goals are reviewed.
• Provide emergency return instructions for seizure, hallucinations, confusion, persistent vomiting, chest pain, severe tremor, or inability to keep medication down.

Notes

Alcohol withdrawal should be treated as both an acute neurophysiologic syndrome and an opportunity to change the longer disease course. Adequate benzodiazepine therapy prevents undertreated withdrawal from escalating, while careful setting selection protects patients with previous seizures, delirium, severe medical illness, or unreliable symptom scoring. Thiamine, metabolic correction, and evaluation for competing diagnoses are part of the acute workup. The admission should not end at detoxification: linkage to alcohol use disorder medication, counseling, and follow-up is a core outcome of good withdrawal care.

References

1. ASAM Clinical Practice Guideline on Alcohol Withdrawal Management — Link